- AI systems can flag mammographic signs of breast cancer up to six years before clinical diagnosis, with 90% specificity, according to a June 2026 study in Radiology drawing on data from over 31,000 patients.
- The CardiOmicScore blood test, introduced by University of Hong Kong researchers in March 2026, predicts six major cardiovascular diseases up to 15 years in advance by scanning thousands of proteins and metabolites.
- Oman’s national diabetic retinopathy programme analysed over 43,000 retinal images at 91.3% accuracy and cut specialist eye clinic wait times by 87%.
A breast cancer diagnosis six years before a tumour becomes clinically detectable. A blood test that flags heart attack risk 15 years out. These are results from studies published in the first half of 2026, and they represent a genuine change in what early disease detection can deliver.
Catching Cancer Early
A June 2026 study in Radiology, drawing on data from over 31,000 patients in Sweden’s national screening programme, found that AI-based computer-assisted detection systems could identify subtle mammographic signs of breast cancer up to six years before a formal diagnosis. The systems reached 90% specificity in distinguishing real positives from false ones, particularly for cancers diagnosed two to six years later. Dr. Fredrik Strand from Karolinska University Hospital noted that roughly 1 in 5 breast cancer cases show signs visible to AI long before any clinical detection.
AI is also being applied to lung and colorectal cancer screening. Deep learning tools can pick out lung nodules in low-dose CT scans and flag polyps during colonoscopies, patterns that human radiologists can miss under high workload. The practical effect is fewer missed diagnoses and faster triage for patients who need follow-up. Our coverage of FDA-cleared AI tools now detecting breast cancer earlier goes deeper on the regulatory picture.
Predicting Heart Risk Years Out
Researchers at the University of Hong Kong introduced CardiOmicScore in March 2026, a blood test that uses AI to predict the risk of six major cardiovascular diseases, including heart attack and stroke, up to 15 years in advance. The system scans thousands of proteins and metabolites, building a picture of a person’s current biology, lifestyle markers and environment. That goes well beyond what standard genetic risk scores can offer.
Mayo Clinic’s AI cardiology team applied similar logic to ECG analysis as early as 2019, developing a screening tool that identifies early signs of left ventricular dysfunction from standard ECGs, including ones that cardiologists had initially read as normal — a foundational result in cardiac AI that the field has continued building on since.
Wearables That Watch Continuously
Smartwatches, fitness trackers and sensor patches now collect enough continuous data, heart rate, blood oxygen, sleep, activity, that AI can detect patterns a single clinic visit would miss. The clearest example is atrial fibrillation detection. A 2024 Scripps Research study, conducted with iRhythm, used a wearable chest patch and deep learning to analyse ECG recordings from over 446,000 participants, producing an AI model for early AF detection. Researchers are also exploring wearable-based detection of seizures, tremors and early-stage respiratory conditions, though most of that work remains in clinical trials.
For conditions that develop quietly over months or years, continuous monitoring offers something no clinic visit can replicate. Our coverage of AI repurposed from mammograms to predict heart disease risk shows how that same principle is playing out in hospital imaging.
Bias and the Black Box Problem
AI models trained on incomplete or skewed patient data can perform well on average and poorly for specific groups: older patients, people from underrepresented ethnic backgrounds, anyone whose demographics were thin in the training set. That is a known failure pattern in deployed medical AI, and it falls hardest on populations that already face worse health outcomes.
There is also the interpretability problem. When an AI flags a scan as high-risk, it often cannot explain why in terms a clinician can verify or a patient can understand. That opacity slows clinical adoption and raises genuine liability questions. Researchers are working on more explainable models, and regulators are beginning to require transparency as a condition of approval, but the gap between what AI can detect and what clinicians can fully trust remains real.
From Pilot to National Programme
Oman’s national diabetic retinopathy screening programme offers the clearest current example of AI moving from research into public health infrastructure. The programme analysed over 43,000 retinal images at 91.3% accuracy and cut specialist eye clinic wait times by 87% by automating the initial screening step, freeing clinicians to focus on cases requiring direct intervention. Diabetic retinopathy can cause vision loss if left undetected, and the volume of patients requiring annual screening routinely outstrips specialist capacity in most health systems. Automating the triage layer addresses that constraint directly. How widely this model is being replicated across other national programmes is harder to verify from public sources, but the Oman results are among the most concrete deployment figures published to date.
